Craig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $62

Benzinga Newsdesk www.benzinga.com Positive 68.1%

Neg 0% Neu 0% Pos 68.1%

Craig-Hallum analyst Chase Knickerbocker maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $40 to $62.